血清CA72-4在痛风患者中特异性升高并可预测发作
本研究通过横断面研究比较痛风性关节炎、无症状高尿酸血症、四种主要关节炎及健康对照的血清CA72-4水平,并以前瞻性痛风队列(随访6个月)验证其预测发作的价值。结果显示CA72-4在痛风性关节炎患者中高表达,高CA72-4水平(>6.9 U/ml)是痛风发作的最强预测因子,秋水仙碱预防对高CA72-4患者有效。
要点
- 痛风性关节炎患者血清CA72-4中位数4.55 U/ml,显著高于高尿酸血症、健康对照及其他关节炎患者(P<0.001)。
- 高CA72-4水平(>6.9 U/ml)是痛风发作的最强预测因子(风险比=3.889)。
- 秋水仙碱预防对高CA72-4水平患者有效(P=0.014)。
核心结论
- CA72-4在频繁发作的痛风患者中上调,是预测未来发作的有用生物标志物。
研究设计与样本
- 横断面研究比较痛风性关节炎、无症状高尿酸血症、四种主要关节炎(OA、RA、SpA、化脓性关节炎)及健康对照的血清CA72-4表达。
- 前瞻性痛风队列研究,随访6个月,在第1、3、6个月观察痛风发作、CA72-4水平及其他痛风相关临床变量。
主要发现
- 痛风性关节炎患者CA72-4中位数(四分位距)为4.55(1.56, 32.64)U/ml,高于高尿酸血症患者1.47(0.87, 3.29)U/ml、健康对照1.59(0.99, 3.39)U/ml及其他关节炎患者(化脓性关节炎1.38(0.99, 2.66)U/ml;RA 1.58(0.95, 3.37)U/ml;SpA 1.56(0.98, 2.85)U/ml;OA 1.54(0.94, 3.34)U/ml;各自P<0.001)。
- 过去一年发作两次或以上的痛风患者CA72-4水平高于发作少于两次的患者。
- 高CA72-4水平(>6.9 U/ml)是痛风发作的最强预测因子(风险比=3.889)。
- 秋水仙碱预防有效,尤其对高CA72-4水平患者(P=0.014)。
关键数值与推荐
- CA72-4高水平的截断值为>6.9 U/ml,用于预测痛风发作。
- 秋水仙碱预防对高CA72-4水平患者有效的P值为0.014。
临床怎么用
- 对痛风患者可检测血清CA72-4水平,高CA72-4水平(>6.9 U/ml)提示未来发作风险高。
- 对高CA72-4水平的痛风患者,可考虑秋水仙碱预防以降低发作风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Serum CA72-4 levels are elevated in some gout patients but this has not been comprehensively described. The present study profiled serum CA72-4 expression in gout patients and verified the hypothesis that CA72-4 is a predictor of future flares in a prospective gout cohort. METHODS: To profile CA72-4 expression, a cross-sectional study was conducted in subjects with gouty arthritis, asymptomatic hyperuricaemia, four major arthritis types (OA, RA, SpA, septic arthritis) and healthy controls. A prospective gout cohort study was initiated to test the value of CA72-4 for predicting gout flares. During a 6-month follow-up, gout flares, CA72-4 levels and other gout-related clinical variables were observed at 1, 3 and 6 months. RESULTS: CA72-4 was highly expressed in patients with gouty arthritis [median (interquartile range) 4.55 (1.56, 32.64) U/ml] compared with hyperuricaemia patients [1.47 (0.87, 3.29) U/ml], healthy subjects [1.59 (0.99, 3.39) U/ml] and other arthritis patients [septic arthritis, 1.38 (0.99, 2.66) U/ml; RA, 1.58 (0.95, 3.37) U/ml; SpA, 1.56 (0.98, 2.85) U/ml; OA, 1.54 (0.94, 3.34) U/ml; P < 0.001, respectively]. Gout patients with frequent flares (twice or more in the last year) had higher CA72-4 levels than patients with fewer flares (fewer than twice in the last year). High CA72-4 level (>6.9 U/ml) was the strongest predictor of gout flares (hazard ratio = 3.889). Prophylactic colchicine was effective, especially for patients with high CA72-4 levels (P = 0.014). CONCLUSION: CA72-4 levels were upregulated in gout patients who experienced frequent flares and CA72-4 was a useful biomarker to predict future flares.
引用
- Bai X, Sun M, He Y, et al. Serum CA72-4 is specifically elevated in gout patients and predicts flares. Rheumatology (Oxford). 2020. PMID: 32087013. doi:10.1093/rheumatology/keaa046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。